Physician profile
Fernando Nicolas Galan
NPI 1427496850
$13,241.19
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $190 · 2021: $69.03 · 2022: $348 · 2023: $343 · 2024: $338 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,620 · Travel and Lodging: $3,255 · Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,620.00 |
| Travel and Lodging | $3,254.56 |
| Food and Beverage | $2,242.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocodex, INC. | $6,562.19 | 2025 | |
| Ucb, INC. | $3,295.98 | 2019-2025 | Fintepla, Briviact |
| Jazz Pharmaceuticals INC. | $2,329.03 | 2022-2025 | |
| Neuropace, INC. | $460.53 | 2019-2025 | |
| Neurelis, INC. | $153.82 | 2021-2025 | Valtoco |
| Livanova USA, INC. | $122.20 | 2019 | |
| Greenwich Biosciences, INC. | $93.42 | 2020-2021 | |
| Monteris Medical Corporation | $58.70 | 2022 | |
| Eisai INC. | $39.58 | 2019 | |
| Aquestive Therapeutics, INC. | $35.99 | 2020 | |
| Upsher-Smith Laboratories LLC | $29.26 | 2025 | |
| Otter Pharmaceuticals, LLC | $25.65 | 2025 | Sympazan |
| Zogenix INC. | $21.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.65 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Galan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.